HS
MRTX

HighVista Strategies’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

HighVista Strategies’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,738
Closed -$569K – 165
2023
Q2 		$569K Hold
15,738
– – 0.26% 115
2023
Q1 		$585K Buy
15,738
+4,035
+34% +$181K 0.48% 68
2022
Q4 		$530K Buy
11,703
+892
+8% +$57.7K 0.31% 73
2022
Q3 		$755K Sell
10,811
-285
-3% -$21.1K 0.43% 62
2022
Q2 		$745K Buy
11,096
+1,343
+14% +$85.4K 0.45% 51
2022
Q1 		$802K Buy
9,753
+517
+6% +$52.9K 0.51% 59
2021
Q4 		$1.35M Buy
9,236
+747
+9% +$116K 1.08% 27
2021
Q3 		$1.5M Buy
8,489
+3,563
+72% +$573K 0.99% 19
2021
Q2 		$796K Buy
4,926
+660
+15% +$106K 0.56% 51
2021
Q1 		$731K Buy
4,266
+703
+20% +$139K 0.54% 35
2020
Q4 		$783K Buy
3,563
+163
+5% +$35.2K 0.5% 48
2020
Q3 		$565K Sell
3,400
-177
-5% -$24.2K 0.41% 32
2020
Q2 		$408K Buy
+3,577
New +$347K 0.34% 60

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighVista Strategies's MRTX Position: Q3 2023 in Review

HighVista Strategies sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 15,738 shares — an estimated $569K sold.

HighVista Strategies first reported a position in MRTX in Q2 2020 and held it in 13 quarters. The position peaked at $1.5M in Q3 2021. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • HighVista Strategies reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • HighVista Strategies sold 15,738 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $569K.
  • HighVista Strategies first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
  • HighVista Strategies's Mirati Therapeutics, Inc. Common Stock position peaked at $1.5M in Q3 2021.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.